2022
DOI: 10.1186/s42466-022-00217-5
|View full text |Cite
|
Sign up to set email alerts
|

No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache

Abstract: Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 6 publications
1
7
0
Order By: Relevance
“…This corroborates with previous reports on milder cases. De Boni et al reported lower levels of Nfl and GFAp in patients with persistent post-COVID-19 headache compared to patients with severe COVID-19 ( 46 ). Lennol et al evidenced normalization of plasma GFAp and Nfl within 2 months following acute infection in patients with or without symptoms of fatigue, headache and memory loss ( 47 ), and Farhadian et al found no evidence of neuroinflammation or blood–brain barrier dysfunction in a cohort of adults with self-reported PCC ( 48 ).…”
Section: Discussionmentioning
confidence: 99%
“…This corroborates with previous reports on milder cases. De Boni et al reported lower levels of Nfl and GFAp in patients with persistent post-COVID-19 headache compared to patients with severe COVID-19 ( 46 ). Lennol et al evidenced normalization of plasma GFAp and Nfl within 2 months following acute infection in patients with or without symptoms of fatigue, headache and memory loss ( 47 ), and Farhadian et al found no evidence of neuroinflammation or blood–brain barrier dysfunction in a cohort of adults with self-reported PCC ( 48 ).…”
Section: Discussionmentioning
confidence: 99%
“…This alignment reinforces the notion that GFAP may serve as a particularly sensitive indicator of CNS involvement in the context of long-COVID syndrome [ 24 ]. Significant associations between elevated GFAP levels and cognitive decline have been reported in female patients with long-COVID [ 25 ], whereas another study has documented lower GFAP levels in the blood of long-COVID individuals also experiencing persistent headaches [ 26 ]. Our findings, however, demonstrated that GFAP levels do not correlate with either the symptomatic manifestation of long-COVID or the performance of individuals in cognitive, mental health, and HQoL assessments.…”
Section: Discussionmentioning
confidence: 99%
“…However, in the study conducted by Telser et al, participants with moderate SARS-CoV-2 infections exhibited neurological symptoms that did not correlate with GFAP levels [ 24 ]. Additionally, De Boni et al reported lower GFAP levels in blood samples from patients experiencing persistent headaches, suggesting that long-COVID-19 headaches might not indicate underlying neuronal damage or neuroinflammation [ 26 ]. Furthermore, Bark et al explored the potential connections between serum GFAP levels, cognitive impairment, and fatigue in long-COVID patients.…”
Section: Discussionmentioning
confidence: 99%
“…A fifth of people with headache in COVID-19 develop a chronic pattern of headache [76]. People with post-COVID-19 symptoms including headache had higher baseline proinflammatory, chemotactic and angiogenic cytokines [77]. Signs of neuro-inflammation and neuroaxonal and glial degeneration, measured with neurofilament light chain and glial fibrillary astrocytic protein, were lower in the blood of people with persistent headache in the phase after the resolution of acute COVID-19 compared to people with severe COVID-19, indicating no neuroaxonal and glial damage or reactive gliosis in people with long-term persistent headache after COVID-19 [78].…”
Section: Headache In the Phase After The Resolution Of Acute Covid-19mentioning
confidence: 99%